PHARMA-Q ADRENALINE INJECTION 1 mg/ml Afrika Selatan - Inggris - South African Health Products Regulatory Authority (SAHPRA)

pharma-q adrenaline injection 1 mg/ml

pharma-q holdings (pty) ltd - injection - see ingredients - each 1 ml liquid contains epinephrine bitartrate 1,80 mg equivalent to epinephrine 1 mg

Medication transfer set Australia - Inggris - Department of Health (Therapeutic Goods Administration)

medication transfer set

ferring pharmaceuticals pty ltd - 41222 - medication transfer set - to be used to administer a medication by injection

Medication transfer straw Australia - Inggris - Department of Health (Therapeutic Goods Administration)

medication transfer straw

fairmont medical products pty ltd - 64357 - medication transfer straw - the disposable mixing cannula or medicine preparation needle / cannula is a made up of a plastic semi rigid tube with an attachment for a syringe in order to aspirate pharmaceutical fluids from vials or ampoules during the preparation of some medicines, this procedure is likely to be performed by pharmacists, physicians or nurses. the device is not capable of skin penetration or injection and is supplied non-sterile for single disposable use

Sugammadex Pharmazac Solution for Injection 100mg/ml (2ml vial) Malta - Inggris - Medicines Authority

sugammadex pharmazac solution for injection 100mg/ml (2ml vial)

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products

Sugammadex Pharmazac Solution for Injection 100mg/ml (5ml vial) Malta - Inggris - Medicines Authority

sugammadex pharmazac solution for injection 100mg/ml (5ml vial)

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products

Amorolfine 5% w/v medicated nail lacquer Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

amorolfine 5% w/v medicated nail lacquer

chanelle medical - amorolfine - medicated nail lacquer - 5 percent weight/volume - amorolfine

Loceryl 5% w/v Medicated Nail Lacquer Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

loceryl 5% w/v medicated nail lacquer

ltt pharma limited - amorolfine - medicated nail lacquer - 5 percent weight/volume - other antifungals for topical use; amorolfine

Versatis 5% medicated plaster Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

versatis 5% medicated plaster

ltt pharma limited - lidocaine - medicated plaster - 5 percent - amides; lidocaine

VORICONAZOLE PHARMA REGULATORY SOLUTIONS 200 Milligram Pdr for Soln for Infusion Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

voriconazole pharma regulatory solutions 200 milligram pdr for soln for infusion

pharma regulatory solutions ltd - voriconazole - pdr for soln for infusion - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidaemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Clopidogrel Acino Pharma Uni Eropa - Inggris - EMA (European Medicines Agency)

clopidogrel acino pharma

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.